Eylea is a recombinant fusion protein, that binds VEGF-A and placental growth factor (PlGF) to inhibit the binding and activation of these cognate VEGF receptors.
The recommended dose for Eylea injection is 2 mg administered by intravitreal injection every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every eight weeks (2 months).
Two Phase 3 clinical studies – View 1 and View 2, which proved the efficacy of Eylea in being clinically equivalent to the ranibizumab, led to the approval.